HPC Offered for PRESERVE Expansion

Conditions

• Bone Marrow Transplant (BMT)

Eligibility Criteria

Sex

ALL

Age

12 Years - 80 Years

Healthy Volunteers

Not accepted

Interventions

• Bone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors) — OTHER
  The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.

Study Details

Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product

Key Dates

Start date

Jun 27, 2024

Status verified

Aug 2025

Primary completion

Aug 31, 2027

Completion

Aug 31, 2029

Study Design

Enrollment

10 participants (estimated)

Arms

• Arm: Ossium HPC, Marrow
  Ossium HPC, Marrow will be provide for infusion on the day of transplant

Primary Outcome Measure

Neutrophil engraftment [ Time Frame: 28 days ]

Central Contacts

• Preethi Prasad, Senior Director Clinical Operations
  415-513-5535
  [email protected]

Locations (4)

Find similar trials in Birmingham, AL